-
Innovation Ranking
NewInnovation Ranking – bluebird bio Inc
bluebird bio Inc (bluebird bio) is a biotechnology company that focuses on the development and commercialization of gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as lentiviral gene addition platform, cancer immunotherapy and gene editing. Its product pipeline includes elivaldogene autotemcel for the treatment of cerebral adrenoleukodystrophy (CALD); betibeglogene autotemcel for transfusion-dependent beta thalassemia; Lovo-cel for the treatment of sickle cell disease, besides compounds under development...
-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lovotibeglogene Autotemcel in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lovotibeglogene Autotemcel in Sickle Cell Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lovotibeglogene Autotemcel in Sickle Cell Disease Drug Details: Lovotibeglogene autotemcel...
-
Product Insights
Post-Transplant Lymphoproliferative Disorder – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Transplant Lymphoproliferative Disorder - Drugs In Development, 2023’, provides an overview of the Post-Transplant Lymphoproliferative Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Transplant Lymphoproliferative Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Sickle Cell Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Sickle Cell Disease - Drugs In Development, 2023’, provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Lymphoproliferative Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Lymphoproliferative Disorders - Drugs In Development, 2023’, provides an overview of the Lymphoproliferative Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lymphoproliferative Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewNet Present Value Model: bluebird bio Inc’s Iovotibeglogene Autotemcel
Empower your strategies with our Net Present Value Model: bluebird bio Inc's Iovotibeglogene Autotemcel report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Bluebird Solar PV Plant
Bluebird Solar PV Plant is a solar PV project located in Kentucky, United States. The project is owned and being developed by Bluebird Solar LLC. The project is at the permitting stage. Empower your strategies with our Bluebird Solar PV Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Product Insights
Net Present Value Model: bluebird bio Inc’s Iovotibeglogene Autotemcel
Empower your strategies with our Net Present Value Model: bluebird bio Inc's Iovotibeglogene Autotemcel report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.